Imamura, Yoshinori
Tanaka, Kaoru
Kiyota, Naomi http://orcid.org/0000-0001-8021-6116
Hayashi, Hidetoshi
Ota, Ichiro
Arai, Akihito
Iwae, Shigemichi
Minami, Shujiro
Yane, Katsunari
Yamazaki, Tomoko
Nagatani, Yoshiaki
Toyoda, Masanori
Takahama, Takayuki
Sakai, Kazuko
Nishio, Kazuto
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology, Japan (26462605, 17K11384)
Article History
Received: 17 August 2021
Accepted: 12 September 2021
First Online: 22 September 2021
Declarations
:
: Naomi Kiyota has received honoraria for Bristol-Myers Squibb and grant support from Bristol-Myers Squibb outside the submitted work. Hidetoshi Hayashi has received honoraria for AstraZeneca, Bristol-Myers Squibb, and Ono Pharma and grant support from Boehringer Ingelheim and Ono Pharma outside the submitted work. Tomoko Yamazaki has received grant support from AstraZeneca, MSD, and Ono Pharma outside the submitted work. Ken-ichi Nibu has received honoraria for Ono Pharma outside the submitted work. Hironobu Minami has received grant support from Bristol-Myers Squib and Pfizer outside the submitted work. The other authors declare that they have no conflict of interest for this study.
: The study protocol was approved by the institutional review board at each participating center. The trial was conducted in accordance with the Declaration of Helsinki. This trial was registered with the UMIN Clinical Trials Registry as UMIN000008333.
: All patients provided written informed consent before study entry.
: All authors consent to the publication of the manuscript in Medical Oncology.